Cutaneous Melanoma Recruiting Phase 1 Trials for Adalimumab (DB00051)

IndicationStatusPhase
DBCOND0040978 (Cutaneous Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04551352A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive MelanomasTreatment